---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-002118"
form_type: "8-K/A"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-01-12T23:59:59+00:00"
generated_at: "2026-06-06T23:47:33.181372+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BC 9M 2023 revenue $86.3M, net income $18.8M; Gyre Therapeutics files financials for acquired entity

## Summary
- BC revenue $86.3M for 9M 2023 vs $77.4M in 9M 2022 (+11.5%); net income $18.8M vs $2.3M.
- Operating income $25.0M in 9M 2023, up from $7.2M in prior year period.
- Cash and CDs total $46.9M as of Sep 30, 2023; equity $83.8M.
- Business combination closed Oct 30, 2023; filing provides required historical financials of BC.
- Pro forma combined financials also filed as Exhibit 99.2.

## SEC filing metadata
- accession: 0001140361-24-002118
- form_type: 8-K/A
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002118/0001140361-24-002118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036124002118/ef20018550_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-002118
- JSON: https://secwatch.observer/filing/0001140361-24-002118.json
- Plain text: https://secwatch.observer/filing/0001140361-24-002118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.